GlobeNewswire

Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab
15/09/2026
Strategic CDMO collaboration strengthens Axiom’s development infrastructure as the company prepares to advance its therapeutic pipeline. SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage [...]
PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers
15/09/2026
● PDUFA Target Action Date Set for March 16, 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolarityBio ® , a late-stage biotechnology company addressing unmet needs in wound healing through innovation in [...]
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
15/09/2026
Milestone continues the progress towards detection of all 20 amino acids by end of 2026 BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a [...]
Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS
15/09/2026
Enrollment advances into Cohort 2 of Phase 1 trial of RPT1G in relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS) U.S. Food and Drug Administration accepts Investigational [...]
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
15/09/2026
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no [...]
Satellos to Present at the 31st Annual Congress of the World Muscle Society
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today [...]
Juniper Biosciences Unveils JBS-002 and JBS-004, Advancing Two Late-Stage Diagnostic Programs to Registration Batch Manufacturing in the Fourth Quarter of 2026
15/09/2026
Prostate cancer and Alzheimer’s disease imaging programs position the Company for FDA submissions in 2027 across two of the fastest-growing segments in molecular imaging BEDMINSTER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE [...]
Transactions in connection with share buy-back program
15/09/2026
Company announcement no. 35 - 26 15 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections
15/09/2026
MELBOURNE, Australia, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]
C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme
15/09/2026
A potent and selective PAD4 inhibitor demonstrates efficacy comparable to an anti-TNFα biologic in a mouse model of arthritis 15 September 2026 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company [...]
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
15/09/2026
CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 glomerulopathy Detailed interim Phase 1 data to be released in a virtual event after [...]
Eleva separates Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies
15/09/2026
Eleva Biologics will seek strategic partnerships for development and manufacturing of first-in-class and previously inaccessible biologics discovered with the Bryotechnology platform One04 Therapeutics will focus on [...]
Children’s National ranked among top children’s hospitals nationwide and highest in the DMV by U.S. News & World Report
15/09/2026
Ranked in all 11 specialties, with top 10 honors in neurology and neurosurgery, cancer, orthopedics, gastroenterology and GI surgery, neonatology, and diabetes and endocrinology Washington, DC, Sept. 15, 2026 (GLOBE [...]
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
15/09/2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “ Company ” [...]
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
15/09/2026
SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health [...]
From Former Patient to Clinical Leader: Oxford Treatment Center Promotes Kate Bell to Outpatient Clinical Manager
15/09/2026
OXFORD, Miss., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Oxford Treatment Center is pleased to announce the promotion of Kate Bell, NCC, LPC , to Outpatient Clinical Manager. Bell first came to Oxford Treatment Center as a [...]
Ascendis Announces Planned $400 Million Share Repurchase Program
15/09/2026
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s [...]
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
15/09/2026
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and [...]
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
14/09/2026
BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum